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a  b  s  t  r  a  c  t
Objective: The aims of this study were to estimate the frequency of left ventricular hypertro-
phy  and to identify variables associated with this condition in under 25-year-old patients
with sickle cell anemia.
Methods: A cross-sectional study was performed of children, adolescents and young adults
with sickle cell anemia submitted to a transthoracic Doppler echocardiography. The mass
of  the left ventricle was determined by the formula of Devereux et al. with correction for
height, and the percentile curves of gender and age were applied. Individuals with rheumatic
and  congenital heart disease were excluded. The patients were divided into two  groups
according to the presence or absence of left ventricular hypertrophy and compared according
to  clinical, echocardiographic and laboratory variables.
Results: A total of 37.6% of the patients had left ventricular hypertrophy in this sample. There
was  no difference between the groups of patients with and without hypertrophy according
to  pathological history or clinical characteristics, except possibly for the use of hydroxyurea,
more  often used in the group without left ventricular hypertrophy. Patients with left ven-
tricular hypertrophy presented larger left atria and lower hemoglobin and hematocrit levels,
reticulocyte index and a higher albumin:creatinine ratio in urine.
Conclusion: Left ventricular hypertrophy was observed in more than one-third of the
young patients with sickle cell anemia with this ﬁnding being inversely correlated to the
hemoglobin and hematocrit levels, and reticulocyte index and directly associated to a higher
albumin/creatinine ratio. It is possible that hydroxyurea had had a protective effect on the
development of left ventricular hypertrophy.© 2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published∗ Corresponding author at: Campus da Saúde, Hospital Universitário, Av
E-mail  address: rosanaci@yahoo.com (R. Cipolotti).
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reserved.by Elsevier Editora Ltda. All rights reserved.. Cláudio Batista, s/n, Sanatório, 49000-000 Aracaju, SE, Brazil.
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ntroduction
ickle cell anemia (SCA) is a multisystemic disease charac-
erized by acute episodes of pain and progressive lesions of
arget organs. It is one of the most common and most severe
onogenic disorders in the world. In Brazil, it is estimated that
500 children are born with sickle cell anemia each year, that is
:1000 live births, and is thus a serious public health problem.1
ardiovascular disease is a frequent clinical manifestation of
eople with sickle cell anemia.
Eccentric left ventricular hypertrophy (LVH), dilation of
he chambers, biventricular dysfunction, pulmonary hyper-
ension and myocardial ischemia are the principal ﬁndings.2–5
atients with SCA frequently have severe anemia that results
n increased cardiac output with minimal or no increase
n cardiac frequency thereby causing dilatation of the left
entricle6 correlated to the hemoglobin (Hb) level.7,8 The
ilated left ventricle adapts to the chronic volume overload by
ypertrophy, thickening the heart muscle and stretching the
yoﬁbrils of the muscle. Hypertrophy allows the left ventricle
o adapt to the chronic volume overload, initially preserving
iastolic compliance and maintaining the ﬁlling pressure at
ormal levels.9 The literature shows that LVH is a common
ondition in sickle cell anemia after the second decade of
ife.10 Diagnosed by transthoracic Doppler echocardiography,
he prevalence of LVH varies between 13 and 86%.7,10–14 In
hronic cases, LVH presents with diastolic3,15,16 and systolic
ysfunction.3,15
Given the high morbimortality, the present article aimed
o estimate the frequency of LVH in children, adolescents and
oung adults with sickle cell anemia and determine variables
ssociated to this condition.
ethod
tudy  design  and  population
 cross-sectional study was conducted of patients between
he ages of 7 and 25 with SCA as conﬁrmed by electrophoresis,
egularly treated in a referral center. All patients were in steady
tate, and were submitted to outpatient transthoracic Doppler
chocardiography. The exclusion criteria were the presence of
heumatic or congenital heart disease. Patients were consec-
tively enrolled and allocated in two groups according to the
resence or absence of LVH.
ransthoracic  Doppler  echocardiography
chocardiographic examinations were performed using a
emio® XG (Toshiba) device by one experienced echocardio-
rapher. Patients were placed in the left lateral decubitus
osition without sedation to perform the echocardiographic
easurements in parasternal and apical acoustic windows
ollowing the recommendations of the American Society
f Echocardiography.17 At least three cycles were analyzed
or each variable. The electrocardiographic exam was per-
ormed concurrently with laboratory tests. The evaluation
f the left ventricle was obtained using the variables: end
iastolic thickness of the interventricular septum (IVS), 1 5;3  7(5):324–328 325
end-diastolic thickness of the posterior wall of the left ven-
tricle (LVPW), left ventricular end-diastolic diameter (LVDD)
and left ventricular end-systolic diameter (LVSD). The rela-
tive wall thickness (RWT) was obtained using the formula:
RWT = (IVS + LVPW)/LVDD. The left ventricular mass index
(LVMI) was calculated using the formula proposed by Devereux
et al.18 in which:
LVMI(g) = 0.8{1.04[(IVS + LVDD + LVPW)3−3LVDD]} + 0.6
Subsequently the result was corrected for the height18,19 and
applied to speciﬁc percentile curves for gender and age.20 LVH
was diagnosed when the LVMI was higher than the 95th per-
centile for gender and age.20
Demographic  and  clinical  data
Data regarding the age, gender, anthropometry (weight,
height), information regarding the diagnosis (age at diagno-
sis, electrophoresis results), previous use of hydroxyurea and
pathological history (leg ulcers, gallstones, stroke, surgical
splenectomy, priapism, acute chest syndrome, hospitaliza-
tions, transfusions and painful crises in the previous year)
were collected through interviews and from medical charts.
Laboratory  data
Data on the blood count, reticulocyte index (corrected by
hematocrit), lactate dehydrogenase and total bilirubin levels,
ferritin, serum creatinine and urea, albumin:creatinine ratio in
urine and 24-hour creatinine clearance were collected during
the week prior to the echocardiography in order to correlate
them with LVH.
Ethical  considerations
This study is part of clinical research in sickle cell anemia
approved by the Research Ethics Committee of the Universi-
dade Federal de Sergipe (number 0173.0.107.000-09). Patients
over 18 years old and the guardians of under 18-year-old
patients signed informed consent forms.
Data  analysis
The results were analyzed using the Statistical Package for
the Social Sciences for Windows version 17.0 (SPSS, Chicago
IL). Categorical variables were analyzed using the chi-squared
distribution or Fisher’s exact test. The Student’s t-test or
Mann–Whitney test were used to compare numerical variables
between the groups. A logistical regression model was used to
evaluate the protective effect of hydroxyurea after the elimi-
nation of possible confusing variables. The level of signiﬁcance
was set for p-values <0.05.
ResultsOne hundred and nine patients with SCA were studied; 56
(51.4%) were male. SCA was diagnosed at a mean age of
69.28 ± 46.09 months and LVH was present in 41 (37.6%)
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Table 1 – Demographic and clinical characteristics of sickle cell anemia patients with and without left ventricular
hypertrophy.
Left ventricular hypertrophy Total p-value
Yes No
Age (years) 14.07  ± 5.55 15.60 ± 5.70 15.03 ± 5.67 0.17
Gender – n (%)
Male 23 (41.1) 33 (58.9) 56 (51.4) 0.57
Female 18 (34) 35 (66) 53 (48.6)
Age at diagnosis (months) 61.42 ± 41.18 74.46 ± 48.76 69.28 ± 46.09 0.21
Hemoglobin S (%) 80.52 ± 15.33 83.93 ± 11.27 82.56 ± 13.06 0.27
Hemoglobin F (%) 5.52 ± 6.62 4.90 ± 5.87 5.15 ± 6.15 1.00
Ulcers – n (%) 3 (7.5) 13 (19.7) 16 (15.1) 0.07
Cholelithiasis – n (%) 9 (22.5) 27 (40.9) 36 (34) 0.08
Stroke – n (%) 4 (10) 12 (18.2) 16 (15.1) 0.20
Splenectomy – n (%) 6 (15) 7 (10.6) 13 (12.3) 0.72
Priapism – n (%) 1 (4.5) 2 (6.3) 3 (5.6) 0.64
ACS – n (%) 23 (59) 49 (75.4) 72 (69.2) 0.12
Hydroxyurea (yes) – n (%) 3 (7.5) 16 (24.2) 19 (17.6) 0.02
Hydroxyurea (months of use) 34.67 ± 3.21 32.50 ± 16.01 32.84 ± 14.68 0.82
Hospitalizations/year 0.72 ± 1.23 0.91 ± 1.36 0.84 ± 1.31 0.47
Pain crises/year 0.51  ± 0.91 0.74 ± 1.23 0.66 ± 1.13 0.44
Transfusions/year 0.77 ± 1.25 1.48 ± 2.74 1.22 ± 2.32 0.31ACS: acute chest syndrome.
patients. The mean age, and the proportions of Hb S and Hb F
were similar between patients with or without LVH. The main
complications resulting from SCA were acute chest syndrome
(69.2%), cholelithiasis (34%), stroke (15.1%) and leg ulcers
(15.1%). Patients presented on average 0.84 ± 1.31 episodes of
hospitalization/year and 0.66 ± 1.13 pain crises that required
hospitalization/year and received 1.22 ± 2.32 units of packed
red blood cells/year; there were no signiﬁcant differences in
respect to these variables between the two groups. Hydrox-
yurea was continuously used by 17.6% of the 109 patients, 7.5%
in the group with LVH and 24.2% in the group without LVH
(p-value = 0.02). The duration of hydroxyurea use was similar
between the two groups (Table 1).
Patients with LVH presented greater LVDD, LVSD, end dia-
stolic thickness of the IVS, end-diastolic thickness of the LVPW
and larger diameters of the aortic root and of the left atria. End-
diastolic volume, ejection fraction and the systolic shortening
fraction were similar between the two groups (Table 2).
The group with LVH presented lower Hb levels
(7.65 ± 1.39 g/dL vs. 8.46 ± 1.70 g/dL; p-value = 0.01), hema-
tocrit concentrations (21.94 ± 3.41% vs. 25.26 ± 5.49%;
p-value = 0.001), reticulocyte index (1.23 ± 0.75 vs. 1.97 ± 1.52;
p-value = 0.02) and a higher 24-h albumin:creatinine ratio
in urine (97.92 ± 217.83 mg/dL vs. 27.60 ± 43.51 mg/dL;
p-value = 0.01). Hemolysis markers (lactate dehydroge-
nase, indirect bilirubin and ferritin) and creatinine clearance
were statistically similar in both groups (Table 3). The logistic
regression model did not conﬁrm any protective effect of
hydroxyurea in this sample.Discussion
LVH was present in 37.6% of the patients included in the
study. There was no difference between groups with respect toclinical, demographic or pathological aspects, with a possible
exception for the use of hydroxyurea. Patients with LVH had a
larger left atria index for body surface and lower hemoglobin
and hematocrit levels, and reticulocyte index and higher
24-h albumin:creatinine ratio in urine. Markers of hemolysis
(lactic dehydrogenase, indirect bilirubin and ferritin) and cre-
atinine clearance were uniformly high in both groups. Using
echocardiography, previous studies have shown that LVH is
a common condition of SCA adults8,9 with a prevalence that
ranges between 13 and 86%, a variation related to the different
criteria used in the studies.7,10–14 Anatomopathological stud-
ies show frequencies for LVH of 20–100% in SCA patients.21
Sickle cell disease patients have higher rates of left ventricu-
lar mass when compared to Hb S heterozygotes, patients with
iron deﬁciency anemia and healthy patients.2,8
In this study, no signiﬁcant difference was identiﬁed
between the groups with respect to age and age at diagnosis.
Several authors have shown that LVH is directly related to the
age3,7,8,15 whereas another study10 showed that LVH is much
more common in young people. Moreover, other authors did
not ﬁnd any difference in age among patients with or without
hypertrophy.12 There was no statistical difference regarding
the percentage of Hb S and Hb F at diagnosis between the
groups in this study. A previous study showed a directly pro-
portional relationship between left ventricular mass and Hb S
levels,7 but not with Hb F.11,22
The continued use of hydroxyurea was a protector against
LVH in the bivariate analysis, but the logistic regression
model did not conﬁrm this ﬁnding, which may be related to
the sample size. There is no reference in previous studies
regarding association between LVH and leg ulcers, cholelithi-
asis, stroke, priapism or acute chest syndrome. Although
statistically similar between groups, the numerical difference
can be considered, as these were the most common morbidi-
ties in patients without LVH, perhaps because of a ‘shield’
rev bras hematol hemoter. 2 0 1 5;3  7(5):324–328 327
Table 2 – Echocardiographic parameters of sickle cell anemia patients with and without left ventricular hypertrophy.
Left ventricular hypertrophy p-value
Yes No
LV mass index (g/m2)a 49.40 ± 9.65 32.94 ± 4.43 <0.001
Aortic root (mm/m2)a 21.9 ± 3 19.7 ± 2.6 <0.001
Left atrium (mm/m2)a 25.5 ± 3.9 22  ± 3.4 <0.001
LV diastolic diameter (mm/m2)a 44.6 ± 7.7 36.7 ± 5.3 <0.001
LV systolic diameter (mm/m2)a 27 ± 5.1 22.2 ± 3.9 <0.001
Interventricular septum (mm/m2)a 6.5 ± 1.2 5.2 ± 0.7 <0.001
LV posterior wall (mm/m2)a 6.6 ± 1.3 5.3 ± 0.8 <0.001
End-diastolic volume (mm3/m2)a 34.77 ± 26.32 26.25 ± 11.93 0.09
Relative wall thickness (mm) 0.30 ± 0.05 0.29 ± 0.04 0.63
Systolic shortening fraction (%) 0.39 ± 0.05 0.39 ± 0.07 0.73
Ejection fraction (%) 0.69 ± 0.64 0.69 ± 0.64 0.99
SPAP (mmHg) 17.89 ± 7.72 20.60 ± 8.75 0.15
LV: left ventricle; SPAP: systolic pulmonary artery pressure.
a Adjusted for body surface.
Table 3 – Laboratory variables of sickle cell anemia patients with and without left ventricular hypertrophy.
LVH p-value
Yes No
Hemoglobin (g/dL) 7.65 ± 1.39 8.46 ± 1.70 0.01
Hemoglobin (%) 21.94 ± 3.41 25.26 ± 5.49 0.001
Leukocytes (mm3) 12,954.00 ± 3460.78 12,007.71 ± 4500.11 0.26
Reticulocyte index 1.23 ± 0.75 1.97 ± 1.52 0.02
Lactate dehydrogenase (U/L) 1576.89 ± 789.76 1310.14 ± 701.96 0.10
Total bilirubin (mg/dL) 4.93 ± 2.93 4.14 ± 3.44 0.25
Indirect bilirubin (mg/dL) 4.11 ± 2.73 3.39 ± 3.23 0.27
Ferritin (ng/mL) 651.57 ± 1313.11 857.95 ± 1271.80 0.46
Creatinine (mg/dL) 0.39 ± 0.14 0.42 ± 0.12 0.22
Urea (mg/dL) 16.17 ± 6.66 15.37 ± 6.05 0.55
Albumin:creatinine (mg/g) 97.92 ± 217.83 27.60 ± 43.51 0.01























ffect given by a possible higher frequency of blood transfu-
ions. Likewise, patients with histories of stroke, priapism and
cute chest syndrome constitute the group with classical indi-
ation for the use of hydroxyurea, which also contributes to
ncreased levels of hemoglobin and a proportionate decrease
n Hb S, previously demonstrated as being directly related to
ncreases in left ventricular mass in SCA patients. The left
trium, a potential marker of diastolic dysfunction, was sig-
iﬁcantly larger in patients with LVH, a result consistent with
revious studies.13,14 Systolic pulmonary artery pressure was
imilar between the groups in this study, thereby disagreeing
ith the literature.14,23
LVH is inversely related to the hemoglobin concentration,
hich is consistent with previous studies.7,8,12 The reticu-
ocyte index, lower in patients with LVH, may signal bone
arrow exhaustion. Markers of hemolysis (lactic dehydroge-
ase, indirect bilirubin and ferritin) and creatinine clearance
ere uniformly high in both groups, possibly due to the pre-
ominant haplotype in Brazil, Bantu, which is associated
24ith the most severe disease. Previous studies showed that
atients who  more  often received red blood cell transfusions
ad lower left ventricular masses,12,25 similar to data found in
he present study, in which numerical, albeit non-signiﬁcant,differences were observed. LVH was not associated to ferritin
levels, similar to a previous study.12 In one study patients
with LVH had a higher mean 24-h albumin:creatinine ratio
in urine, with similar glomerular ﬁltration rates between the
two groups.12 Patients were described as chronically anemic,
with established renal impairment, dilation of the left ven-
tricle and LVH in another study,26 reinforcing the difference
found in the albumin:creatinine ratio, although there was no
relation to the glomerular ﬁltration rate. This is possibly due
to the state of hyperﬁltration, characteristic of early renal
injury in SCA patients. In one study cardiac remodeling was
prevented with the use of enalapril in nine SCA patients.27
Although the association of increased left ventricular mass
and diastolic dysfunction is related to hypertension in the
general population, in SCA patients this association is due
to a combination of compensatory hypertrophy of the left
ventricle, secondary anemia and left ventricular dilatation
along with systemic vasculopathy. Direct myocardial injury
and microvascular disease by iron deposition have been pos-
17tulated as possible etiologies for cardiac abnormalities. The
dilated left ventricle allows an adaptation to chronic volume
overload, initially preserving diastolic compliance and main-
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ventricular diastolic3,15,17 and systolic dysfunction3,15 and has
been described as a cause of sudden death in SCA patients.10
This study presents limitations. The criteria used to deﬁne
LVH are designed for more  ethnically homogeneous popula-
tions. Moreover, arterial blood pressures were not evaluated.
The low number of patients using hydroxyurea may have
interfered in the adequate analysis of a possible protective
role.
Conclusion
Young SCA patients in this study had a high prevalence of
LVH (37.6%); this was associated with lower hemoglobin and
hematocrit levels and reticulocyte index and a higher albu-
min:creatinine ratio.
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